Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMMONUL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
FDA: Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders.,Off-label: Management of hyperammonemia due to other causes (e.g., valproate toxicity, organic acidemias).
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Phenylacetate: 0.5-1 hour; phenylacetylglutamine: 1-2 hours. Clinical context: rapid clearance; requires continuous IV infusion for sustained effect.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Sodium phenylacetate is metabolized via conjugation with glutamine (by glutamine N-phenylacetyltransferase) to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine (by benzoyl-Co A:glycine N-acyltransferase) to form hippurate. Both conjugates are rapidly excreted by the kidneys.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Renal: >80% (primarily as phenylacetylglutamine). Biliary/fecal: <5%.
Negligible for electrolytes and dextrose (<5%).
Phenylacetate: 82% bound to albumin; phenylacetylglutamine: 51% bound.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Phenylacetate: 0.3-0.5 L/kg; phenylacetylglutamine: 0.1-0.2 L/kg. Indicates distribution primarily in extracellular fluid.
Intravenous: 100%.
Oral: Not available; sodium phenylacetate/sodium benzoate is administered intravenously only.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Contraindicated in severe renal insufficiency (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min): reduce dose by 50%. For mild impairment (Cr Cl 50-80 m L/min): no adjustment needed.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
No specific guidelines based on Child-Pugh; use with caution in severe hepatic impairment. Monitor ammonia levels.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Same weight-based area (2.5 g/m²) as adults. For neonates and infants, dosage calculated per body surface area. Administration route and frequency identical to adults.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
No specific dose adjustment; use caution due to age-related renal decline. Monitor renal function and ammonia levels.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Ammonul must be administered with arginine to prevent arginine deficiency and worsening hyperammonemia. Neurotoxicity (including seizures, cerebral edema, and death) may occur if not properly monitored. Extravasation can cause severe tissue necrosis; ensure proper IV access.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Monitor plasma ammonia levels, electrolytes, and blood counts closely.,Risk of hypernatremia (high sodium load); adjust fluid and sodium intake.,Extravasation risk: administer through a central line if possible; treat extravasation immediately.,May cause hyperventilation and metabolic acidosis.,Use with caution in patients with hepatic or renal impairment.,Contains sodium benzoate; possible hypersensitivity reactions.
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Known hypersensitivity to any component of Ammonul.,Pre-existing severe hypernatremia.,Concomitant use with other drugs containing sodium benzoate or sodium phenylacetate.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Take with food or meals to reduce gastrointestinal distress. Avoid high-protein supplements or foods that may increase ammonia levels; dietary protein restriction should be managed by a dietitian.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential risk unknown; second/third trimester: may cause maternal ammonia accumulation if subtherapeutic, but drug is essential for urea cycle disorders. Risk of untreated hyperammonemia outweighs potential teratogenic risk.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No human data on excretion in breast milk; M/P ratio unknown. Caution advised; consider risk of infant hyperammonemia vs. benefit of breastfeeding.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Monitor ammonia levels closely; pregnancy may increase metabolic demands. Dose adjustments based on ammonia levels: usual dose is weight-based (e.g., 5.5 g/m²/day for sodium phenylacetate/sodium benzoate). Consider increased clearance during pregnancy? No specific data; empiric adjustments based on ammonia levels recommended.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
AMMONUL (sodium phenylbutyrate) is used as a nitrogen-binding agent in urea cycle disorders. Monitor plasma ammonia levels closely; target <60 μmol/L. Administer with food to reduce GI irritation. Not recommended in patients with severe hepatic impairment due to reduced conversion to phenylacetate. Contraindicated in pregnancy (category C).
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
Take exactly as prescribed; do not skip doses.,May cause nausea, vomiting, or diarrhea; take with food.,Avoid use of valproic acid or corticosteroids unless directed.,Contact provider if symptoms of hyperammonemia occur (vomiting, lethargy, confusion).,Women of childbearing potential should use effective contraception.,Store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMMONUL, answered by our medical review team.
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. AMMONUL is a Ammonia Detoxicant that works by Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and AMMONUL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. The standard adult dose of AMMONUL is: For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER and AMMONUL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. AMMONUL is classified as Category C. Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.